Annovis Bio Inc ANVS

NYS: ANVS | ISIN: US03615A1088   14/11/2024
6,970 USD (-5,94%)
(-5,94%)   14/11/2024

8 juni 2023 · Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace · Persbericht

20 april 2023 · ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST · Persbericht

19 april 2023 · ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST · Persbericht

13 april 2023 · Annovis Bio To Hold Live Webcast To Review Alzheimer's Disease And Parkinson's Disease Clinical Programs · Persbericht

11 april 2023 · Annovis Bio Raises Aggregate Gross Proceeds Of Approximately $8.7 Million · Persbericht

3 april 2023 · Annovis Bio Announces Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update · Persbericht

22 maart 2023 · Annovis Bio Announces Two Presentations At The Ad/Pd™ 2023 International Conference On Alzheimer's And Parkinson's Diseases · Persbericht

8 februari 2023 · Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease · Persbericht

1 februari 2023 · Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses · Persbericht

25 januari 2023 · Annovis Bio Announces Patient Enrollment Update For Phase 3 Study Of Buntanetap For The Treatment Of Parkinson's Disease · Persbericht

6 januari 2023 · Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team · Persbericht

8 november 2022 · Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update · Persbericht

20 oktober 2022 · Annovis Bio to Present at the 2022 ThinkEquity Investor Conference · Persbericht

11 oktober 2022 · Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease · Persbericht

6 oktober 2022 · Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease · Persbericht

29 september 2022 · Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference · Persbericht

13 september 2022 · Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases · Persbericht

8 september 2022 · Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders · Persbericht

29 augustus 2022 · Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer · Persbericht

24 augustus 2022 · Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease · Persbericht

Mijn selecties